A kidney disease medication, finerenone, is showing promise in restoring fertility for women experiencing premature ovarian insufficiency (POI), according to research published this week in the journal Science.
POI, affecting more than 1% of women, is characterized by the loss of ovarian function before the age of 40, leading to menstrual irregularities and infertility. Currently, there are no established treatments to reverse infertility associated with the condition, as patients typically lack hormone-responsive follicles. The study details a screening process of FDA-approved drugs that identified finerenone as a potential therapeutic agent.
Researchers found that finerenone stimulated follicle development in aged mice and, crucially, restored antral follicle development in women diagnosed with POI. This restoration resulted in the production of mature oocytes and embryos. The mechanism of action appears to center on reducing fibrotic deposition within the ovarian stroma, thereby alleviating collagen-mediated suppression of follicular development, according to the study.
The research team, led by scientists who identified the ovarian stroma—rather than the follicles themselves—as the key therapeutic target, also identified other FDA-approved antifibrotic drugs that may hold potential for treating POI-related infertility. This suggests a broader avenue for therapeutic intervention beyond finerenone specifically.
The findings, published February 5, 2026, build upon earlier research highlighting the importance of the ovarian stroma in POI. A 2022 review published in Reproductive Biology and Endocrinology noted that hormone replacement therapy remains the primary treatment for POI, addressing symptoms but not the underlying infertility.
Medical professionals have long sought effective treatments for POI, a condition that impacts an estimated up to 3% of women under 40, as reported by Medical Xpress. The discovery of finerenone’s potential offers a latest direction for research and potential clinical application.
Further research is underway to determine the long-term efficacy and safety of finerenone and other antifibrotic drugs in treating POI-related infertility. No immediate timeline for clinical trials or widespread availability has been announced.
